SECOND TRIMESTER ABORTION: MIFEPRISTONE PLUS
MISOPROSTOL vs. MISOPROSTOL PLUS OXYTOCIN
AIDA PETCA 1#, MONA ZVANCA 1#, MIHAELA BOȚ 1, RAZVAN-COSMIN PETCA 2*, CLAUDIA MEHEDINȚU 3, SILVIUS NEGOIȚA 4#, NICOLETA MARU 5
1Department of Obstetrics and Gynaecology, Elias Emergency Hospital, “Carol Davila” University of Medicine and Pharmacy,
Bucharest, Romania
2Department of Urology, “Prof. Dr. Th. Burghele” Clinical Hospital “Carol Davila” University of Medicine and Pharmacy,
Bucharest, Romania
3Department of Obstetrics and Gynaecology, Malaxa Clinical Hospital, “Carol Davila” University of Medicine and Pharmacy,
Bucharest, Romania
4Department of Anaesthesiology and Critical Care, Elias Emergency Hospital, “Carol Davila” University of Medicine and Pharmacy,
Bucharest, Romania
5Department of Anatomy, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
*corresponding author: drpetca@gmail.com
#Authors with equal contribution
Download Full Article

Abstract:
The study compares outcomes from simultaneous administration of Mifepristone and Misoprostol (M&M) with a regimen in which
Misoprostol is associated with Oxytocin (M&O) for second-trimester abortion. The primary outcome was uterine evacuation
within 12 hours after the first Misoprostol dose, secondary outcomes were adverse effects, post-abortion complications and
average cost per patient for each method. 108 patients were enrolled with equal distribution and abortion was complete in both
groups. In the M&M group the induction-abortion interval (I-AI) was less than 12 hours in 62.96% (n = 34) compared with the
M&O group with 22.22% (n = 12), p < 0.05. Both regimens had high acceptability rates. We did not find any statistical
difference in adverse effects observed between the two groups. Administering M&M simultaneously resulted in grater expulsion
rates within 12 hours compared with M&O, with the latter regimen demonstrating synergistic benefits, with lower expenses and
satisfactory I-AI.

Top